Maze Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
MAZE$35.45+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
Index to financial statements
| Report of independent auditors (PCAOB ID: 42) | 111 | |
|---|---|---|
| Financial statements as of and for the years ended December 31, 2024 and 2023: | ||
| Balance sheets | 112 | |
| Statements of operations and comprehensive income (loss) | 113 | |
| Statements of redeemable convertible preferred stock and stockholders’ deficit | 114 | |
| Statements of cash flows | 115 | |
| Notes to the financial statements | 116 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.